Press coverage about Sorrento Therapeutics (NASDAQ:SRNE) has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sorrento Therapeutics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.9093368534159 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

Shares of Sorrento Therapeutics (SRNE) opened at $6.80 on Monday. The company has a quick ratio of 0.54, a current ratio of 0.54 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $539.39, a price-to-earnings ratio of -16.19 and a beta of 1.94. Sorrento Therapeutics has a one year low of $1.50 and a one year high of $8.25.

A number of equities analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Sorrento Therapeutics in a report on Thursday, February 1st. BidaskClub raised shares of Sorrento Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. ValuEngine raised shares of Sorrento Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, Oppenheimer set a $6.00 price objective on shares of Sorrento Therapeutics and gave the stock a “buy” rating in a report on Wednesday, November 15th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Sorrento Therapeutics currently has an average rating of “Buy” and a consensus price target of $13.67.

In other Sorrento Therapeutics news, major shareholder Pacific Medtech (Bvi) Ltd Asia sold 684,288 shares of the firm’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $7.56, for a total value of $5,173,217.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Abg Management Ltd sold 150,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $7.19, for a total value of $1,078,500.00. The disclosure for this sale can be found here. Insiders sold 1,215,009 shares of company stock worth $9,185,885 over the last quarter. 5.00% of the stock is currently owned by company insiders.

WARNING: “Sorrento Therapeutics (SRNE) Getting Somewhat Positive News Coverage, Analysis Finds” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://theolympiareport.com/2018/02/12/sorrento-therapeutics-srne-getting-somewhat-positive-news-coverage-analysis-finds.html.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.

Insider Buying and Selling by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.